BASIC RESEARCH ARTICLE

 

Part I: Metabolic bone disease: Histomorphometry as a diagnostic aid

 

 

EJ Raubenheimer

MChD, PhD, DSc. Chief Specialist, Faculty of Health Sciences, MEDUNSA Campus, University of Limpopo

Correspondence

 

 

---

ABSTRACT

Metabolic diseases affecting bone are generally diagnosed late when patients present clinically with end stage skeletal debilitation. This is the result of their subclinical progression and the lack of unequivocal biochemical-or radiological techniques to identify bone changes at an early stage. This manuscript presents histomorphometry as a quantifiable method for the accurate assessment of metabolic bone disease at cellular level.

---

 

 

“Full text available only in PDF format”

 

 

References

1. Lonzer MD, Imrie R, Rogers D. Effects of hereditary, age, weight, puberty, activity and calcium intake on bone and mineral density in children. Clin Pediatr 1996;35:185-9.         [ Links ]

2. Steinche T. Bone histomorphometry in the pathophysiological evaluation of primary and secondary osteoporosis and various treatment modalities. APMIS suppl. 1995; 51:1-44.         [ Links ]

3. Marotti G. A new theory of bone lamellation. Calcif Tissue Int 1993;53(suppl):S47-S56.         [ Links ]

4. Guise TA, Mundy GR. Cancer and bone. Endocrine Rev 1998;19:18-54.         [ Links ]

5. Parfitt AM, Matthews CHE, Villeneuve AR, Kleerekoper M. Relationship between surface, volume and thickness of iliac trabecular bone in ageing osteoporosis. J Clin Invest 1983;72:1396-409.         [ Links ]

6. Jowsey J (ed). Metabolic diseases of bone. Philadelphia: W B Saunders Company; 1977: 229-47.         [ Links ]

7. Issacks PS, Helfet DL, Lane JM. Role of Wnt signaling in bone remodeling and repair. HSS J 2008;4(1):66-70.         [ Links ]

8. Nyssen-Behets C, Dhem A. The fate of quiescent surfaces of lamellar bone. Gerontology 1992;38:153-9.         [ Links ]

9. Delmas PD. Biochemical markers for bone turnover for the clinical assessment of metabolic bone disease. Endocrin Metab Clin North Am 1990;19:1-19.         [ Links ]

10. Eyre D. Collagen crosslinking amino-acids. Methods Enzymol 1987;144:115-39.         [ Links ]

11. Uebelhart D, Gineyts E, Delmas PD. Urinary excretion of pyridinium crosslinks, a marker for bone turnover. J Bone Min Res 1989;4(suppl 1):S407.         [ Links ]

12. Robins S, Stewart P, Ashbury C. Measurement of the cross-linking compound pyridinoline, in urine as an index of collagen degradation in joint disease. Ann Rheum Dis 1986;45:969-73.         [ Links ]

13. Giampietro PF, Peterson MG, Schneider R, Davis JG, Burke SW, Boachie-Adjei O, Raggio CL. Bone mineral density determinations by dual-energy-x-ray absorptiometry in the management of patients with Marfan syndrome - some factors which affect the measurement. HSS J 2007;3(1):89-92.         [ Links ]

14. Vigorita VJ. The tissue pathological features of metabolic bone disease. Orthop Clin North Am 1984;15:613-29.         [ Links ]

15. Amala I. Use of histological methods in studies of osteoporosis. Calcif Tissue Int 1991;49(suppl):531-2.         [ Links ]

16. Jowsey J (ed). Metabolic diseases of bone. Philadelphia: W B Saunders Company; 1977:138-56.         [ Links ]

17. Raubenheimer EJ, van Heerden WFP, Potgieter D. Static and dynamic bone changes in hospitalized patients suffering from rickets - a histomorphometric study. Histopathology 1997;31:12-7.         [ Links ]

 

 

Reprint requests:
Prof EJ Raubenheimer
Room FDN324, Medunsa Campus.University of Limpopo
0204, South Africa
Tel: (012) 521-4838
Email: ejraub@ul.ac.za

 

 

This article was not submitted to an ethical committee for approval. The content of this article is the sole work of the author. No benefits of any form have been derived from any commercial party related directly or indirectly to the subject of this article.